Billiontoone (NASDAQ:BLLN) Insider Nancy Joann Johnson Sells 801 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 801 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $124.91, for a total transaction of $100,052.91. Following the transaction, the insider directly owned 21,099 shares in the company, valued at $2,635,476.09. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54.
• On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The stock was sold at an average price of $99.28, for a total transaction of $339,339.04.

Billiontoone Price Performance

Shares of NASDAQ BLLN opened at $122.59 on Tuesday. The company has a market capitalization of $5.64 billion and a PE ratio of 225.55. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The stock’s 50 day moving average price is $97.00 and its 200-day moving average price is $88.08. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $138.70.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. The business’s revenue was up 83.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.39) earnings per share. On average, equities analysts anticipate that Billiontoone, Inc. will post 0.93 EPS for the current year.

Wall Street Analysts Forecast Growth

BLLN has been the topic of several research reports. Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Guggenheim began coverage on shares of Billiontoone in a research note on Monday, June 29th. They set a “buy” rating and a $125.00 price target for the company. JPMorgan Chase & Co. lifted their price target on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, BTIG Research reduced their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Billiontoone currently has an average rating of “Moderate Buy” and an average target price of $126.00.

Institutional Investors Weigh In On Billiontoone

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rossby Financial LCC bought a new position in shares of Billiontoone in the fourth quarter valued at approximately $25,000. Wells Fargo & Company MN bought a new position in Billiontoone in the 4th quarter valued at $76,000. Smartleaf Asset Management LLC bought a new position in Billiontoone in the 4th quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Billiontoone during the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC purchased a new position in shares of Billiontoone during the 4th quarter valued at $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.